Investment

Deal of the Week: Family office backs cutting edge technologies to fight neurological disorders

Efforts to find better therapies for neurological disorders such as Alzheimer’s received support in a series of deals backed by a family office at the forefront of funding brain disease and injury research. 

San Francisco-based Dolby Family Ventures has backed two ventures in the past week working to find cures and therapies for neurological disorders. The family office is owned and run by Dave Dolby, the son of Ray Dolby, who founded Dolby Laboratories, most famous for its Dolby sound innovations. 

Dolby Family Ventures was one of six investors committing $31 million to Salvia BioElectronics. The Dutch group is involved in the emerging field of “BioElectronics” to restore health for people suffering from severe neurologic disorders such as Alzheimer’s. Founded in 2017, Salvia has already received $35 million in funding, although Dolby Family Ventures is the first significant family office investor. 

In the same week, the family office also backed NeuroTherpia, which is developing new therapies for diseases with an underlying component of neuroinflammation such as Alzheimer’s. Dolby Family Ventures committed $8.8 million with three other investors, including the Alzheimer’s Drug Discovery Foundation, to the Ohio-based group. 

Both investments were at a Series A level. 

Dolby Family Ventures has concentrated much of its biotech investing in ventures looking for cures and better therapies for Alzheimer’s, which, according to Dave Dolby, is due to his desire to find a cure for the disease because his father suffered from it, before succumbing to leukaemia in 2013. 

Subscribe

You will need a Premium Plus Subscription to access this database.

Exclusive news, analysis and research on global family enterprise and private investment offices.

Access to the most comprehensive fully interactive database on global family offices, principal investment offices, and family enterprises.

Check Deal Data, Senior Staff, and New Analysis on more than 500 family/principal investment and holding groups

Already have an account? Login

Subscribe

You need at least a Premium Subscription to read this article.

The most comprehensive information service on the global family enterprise world, featuring exclusive news, analysis, research and data on global family enterprises, family offices, and private investment offices.

Premium

£299

per year

  • Exclusive reports, analysis and commentary
  • Exclusive access to family/private investment office deal information
  • Exclusive interviews with principals and senior management of family/investment offices
SUBSCRIBE NOW

Premium+

£399

per year

  • Access to All of Premium
  • Access to all of FamilyCapital Analytics, our interactive database with more than 500 detailed profiles of family investment groups

More Info

SUBSCRIBE NOW

Already have an account? Login

You've reached the end.

Continue reading free articles by registering as a Member.
Or choose a Premium Plan.

Membership

Free

  • Exclusive reports, analysis and commentary
REGISTER NOW

Premium

£299

per year

  • Exclusive reports, analysis and commentary
  • Exclusive access to family/private investment office deal information
  • Exclusive interviews with principals and senior management of family/investment offices
SUBSCRIBE NOW

Premium+

£399

per year

  • Access to All of Premium
  • Access to all of FamilyCapital Analytics, our interactive database with more than 500 detailed profiles of family investment groups

More Info

SUBSCRIBE NOW

Already have an account? Login

Leave a Reply